Your shopping cart is currently empty

Anticancer agent 109 (compound 6-15) acts as an inhibitor targeting the Gas6-Axl axis, demonstrating significant anti-cancer properties. This compound suppresses the expression of Gas6, Axl, p-PI3K, and p-AKT in cancer cells, thereby inducing G1 phase arrest and promoting apoptosis of cancer cells. Additionally, Anticancer agent 109 effectively inhibits tumor growth in nude mouse tumor-bearing models [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Anticancer agent 109 (compound 6-15) acts as an inhibitor targeting the Gas6-Axl axis, demonstrating significant anti-cancer properties. This compound suppresses the expression of Gas6, Axl, p-PI3K, and p-AKT in cancer cells, thereby inducing G1 phase arrest and promoting apoptosis of cancer cells. Additionally, Anticancer agent 109 effectively inhibits tumor growth in nude mouse tumor-bearing models [1]. |
| In vitro | Anticancer Agent 109 (10 μM, 48 hours) inhibits Gas6 and Axl in A549 cells and suppresses Gas6-Axl axis related proteins in PANC-1 cells, induces G1 phase arrest, and promotes late apoptosis without altering DNA synthesis [1]. Cell viability assays [1] on cell lines including MCF-7, PANC-1, MDA-MB-231, HT-29, DU145, U937, and A549 with a concentration of 30 μM for 48 hours show inhibition of cancer cell growth with up to 20-fold less toxicity to normal cells and up to 5.4 times higher anticancer activity compared to Sunitinib. Growth inhibition IC50 values are 2.0 μM (MCF-7), 2.8 μM (MDA-MB-231), 4.6 μM (HT-29), 1.1 μM (DU145), 6.7 μM (U937), 4.2 μM (A549), and 4.0 μM (PANC-1). Apoptosis analysis [1] in PANC-1 at concentrations of 1 μM, 5 μM, and 10 μM for 48 hours increases sub-G1 fraction and induces late apoptosis. Western Blot analysis [1] at a concentration of 10 μM for 48 hours in A549 and PANC-1 cells demonstrates inhibition of Gas6 and Axl, increased Bax/Bcl-2 expression ratio, and suppression of p-PI3K and p-AKT in PANC-1 cells. RT-PCR [1] on PANC-1 at concentrations of 3 μM, 5 μM, and 10 μM for 48 hours also confirms inhibition of Gas6 and Axl. |
| In vivo | Anticancer agent 109, when administered at 3 mg/kg via intraperitoneal injection (i.p.) six times a week, significantly reduced the size and weight of tumors in xenograft models using BALB/c-nu mice, particularly in A549 tumors over 31 days and PANC-1 tumors over 85 days [1]. The dosage of 1 mg/kg resulted in approximately 75% tumor reduction in A549 models, while 3 mg/kg achieved similar outcomes in PANC-1 models, although tumors were not completely eradicated in the A549 models. |
| Molecular Weight | 317.34 |
| Formula | C19H15N3O2 |
| Cas No. | 2097497-16-8 |
| Smiles | C(=C\1/C=2C(NC1=O)=NC(C)=C(O)C2C)\C3=NC4=C(C=C3)C=CC=C4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.